Brazil has approved the world"s first single-dose vaccine for dengue fever, known as Butantan-DV. This vaccine was developed by the U.S. National Institutes of Health (NIH) and ATCC. It is set to be incorporated into Brazil"s national immunization program in early 2026.
The introduction of Butantan-DV marks a significant advancement in the fight against dengue fever, which poses a public health challenge in many regions. The approval of this vaccine is expected to enhance the country"s efforts to control the spread of the disease.
For more information on related coverage, see recent developments in political matters.
Image for Brazil approves world"s first single-dose dengue vaccine for 2026
